NC
GNMK

Northpointe Capital’s GenMark Diagnostics, Inc GNMK Stock Holding History

Northpointe Capital’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,552,740
Closed -$15M – 193
2017
Q3 		$15M Buy
1,552,740
+304,232
+24% +$3.16M 1.6% 9
2017
Q2 		$14.8M Buy
1,248,508
+171,312
+16% +$2.19M 1.55% 6
2017
Q1 		$13.8M Buy
1,077,196
+217,847
+25% +$2.62M 1.51% 7
2016
Q4 		$10.5M Sell
859,349
-538,939
-39% -$6.4M 1.05% 30
2016
Q3 		$16.5M Sell
1,398,288
-114,446
-8% -$1.1M 1.71% 6
2016
Q2 		$13.2M Buy
1,512,734
+510,472
+51% +$3.5M 1.56% 10
2016
Q1 		$5.28M Sell
1,002,262
-214,219
-18% -$1.19M 0.66% 50
2015
Q4 		$9.57M Hold
1,216,481
– – 1.26% 16
2015
Q3 		$9.57M Buy
+1,216,481
New +$11.3M 1.25% 16

Other funds holding GNMK

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Northpointe Capital's GNMK Position: Q4 2017 in Review

Northpointe Capital sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2017, closing a stake of 1,552,740 shares — an estimated $15M sold.

Northpointe Capital first reported a position in GNMK in Q3 2015 and held it in 9 quarters. The position peaked at $16.5M in Q3 2016. 99 funds tracked by Wall St. Rank hold GNMK as of Q4 2017.

  • Northpointe Capital reported no remaining GenMark Diagnostics, Inc position as of Q4 2017 after selling out during the quarter.
  • Northpointe Capital sold 1,552,740 GenMark Diagnostics, Inc shares in Q4 2017, an estimated $15M.
  • Northpointe Capital first reported a position in GenMark Diagnostics, Inc in Q3 2015 and held it in 9 quarters.
  • Northpointe Capital's GenMark Diagnostics, Inc position peaked at $16.5M in Q3 2016.
  • 99 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2017.

Based on Northpointe Capital's 13F filing for Q4 2017, filed 23 Jan 2018.